Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University
News Jan 16, 2009
Beactica has announced a new research collaboration agreement with GE Healthcare and Uppsala University (Sweden). The collaboration combines Beactica's approach to fragment-based drug discovery and GE Healthcare's Biacore™ technology with enzymology expertise from Uppsala University.
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore™ surface plasmon resonance instruments and applications for fragment-based drug discovery.
The project also aims to identify high-quality leads against a clincally important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018